Cancers, Vol. 16, Pages 1453: Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma

Cancers, Vol. 16, Pages 1453: Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma Cancers doi: 10.3390/cancers16081453 Authors: Sami Fares Chase J. Wehrle Hanna Hong Keyue Sun Chunbao Jiao Mingyi Zhang Abby Gross Erlind Allkushi Melis Uysal Suneel Kamath Wen Wee Ma Jamak Modaresi Esfeh Maureen Whitsett Linganna Mazhar Khalil Alejandro Pita Jaekeun Kim R. Matthew Walsh Charles Miller Koji Hashimoto Andrea Schlegel David Choon Hyuck Kwon Federico Aucejo Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and the sixth most diagnosed malignancy worldwide. Serum alpha-fetoprotein (AFP) is the traditional, ubiquitous biomarker for HCC. However, there has been an increasing call for the use of multiple biomarkers to optimize care for these patients. AFP, AFP-L3, and prothrombin induced by vitamin K absence II (DCP) have described clinical utility for HCC, but unfortunately, they also have well established and significant limitations. Circulating tumor DNA (ctDNA), genomic glycosylation, and even totally non-invasive salivary metabolomics and/or micro-RNAS demonstrate great promise for early detection and long-term surveillance, but still require large-scale prospective validation to definitively validate their clinical validity. This review aims to provide an update on clinically available and emerging biomarkers for HCC, focusing on their respective clinical strengths and weaknesse...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research